IP Library Granted Patent US 11,981,899
Granted Patent B2
US 11,981,899 · App. 18/060,797 · Granted May 14, 2024

Patent

Inventors: Andrew Bristol (Rockville, MD); Michael Kaleko (Rockville, MD); Steven Hubert (Rockville, MD)
Assignee: Theriva Biologics, Inc.
C12N15/70C12N9/86C12N15/67C12P21/02C12Y305/02006C12N15/09C12N15/75
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,981,899
App. No.
18/060,797
Granted
May 14, 2024
Kind
B2
Abstract

The invention relates to, in part, improved methods for the production of beta-lactamase using Escherichia coli ( E. coli ) cells. High yield production of beta-lactamase is achieved using methods of the invention.

Claims (12)

1. A method for the production of a beta-lactamase polypeptide in Escherichia coli ( E. coli ), comprising:

(a) providing a host E. coli cell transformed with an expression vector comprising a sequence encoding the beta-lactamase polypeptide;

(b) culturing the E. coli cell to induce expression of the beta-lactamase polypeptide in the cytoplasm; and

(c) recovering the beta-lactamase polypeptide from a cytoplasmic soluble fraction prepared from the E. coli cell;

wherein the beta-lactamase polypeptide is not recovered or purified from a periplasmic fraction, a cell envelope fraction, a cytoplasmic insoluble fraction, an inclusion body, or an extracellular fraction of the E. coli cell, and

wherein expression of the beta-lactamase polypeptide in the cytoplasm is induced by adding isopropylthiogalactoside (IPTG) to the culture.

2. The method of claim 1 , wherein the method yields more than 10 grams of the beta-lactamase polypeptide per liter of culture.

3. The method of claim 1 , wherein the method yields more than 15 grams of the beta-lactamase polypeptide per liter of culture.

4. The method of claim 1 , wherein the E. coli cell is selected from BL21(DE3) or W3110.

5. The method of claim 1 , wherein the expression vector comprises palindromic DNA looping.

6. The method of claim 1 , wherein the expression vector is suitable for tightly controlled gene expression.

7. The method of claim 1 , wherein the production comprises a single chromatography column step.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2023
From: HUBERT, STEVEN
To: SYNTHETIC BIOLOGICS, INC.
Reel/Frame 062824/0039 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2023
From: BRISTOL, ANDREW; KALEKO, MICHAEL
To: SYNTHETIC BIOLOGICS, INC.
Reel/Frame 062824/0042 →
CHANGE OF NAME Recorded Feb 28, 2023
From: SYNTHETIC BIOLOGICS, INC.
To: THERIVA BIOLOGICS, INC.
Reel/Frame 062824/0046 →
Continuity (4)
Continuation 17314583 · May 7, 2021
Continuation 15506342
Provisional Application 62043360 · Aug 28, 2014
Related Publication 20230279409A1 · Sep 7, 2023